Ensuring consistency of SEND Datasets
PhUSE CSS March Poster_Ensuring consistency of SEND Datasets with Study Reports using Machine Learning Algorithms
PointCross Testing
The Molecular Medicine Tri Con Conference 2018
Kavan Palangappa2024-06-14T06:11:33+00:00Feb 11 – 16, 2018 | San Francisco, CA | Booth # 732
PhuSE Single Day Event Foster City
Kavan Palangappa2024-06-14T06:11:33+00:00Feb 22, 2018 | Foster City Community Center | Wind Room
PhUSE CSS Computational Science Symposium
Kavan Palangappa2024-06-14T06:11:34+00:00March 4 – 6, 2018 | Silver Spring, MD
Benchmark your SEND Readiness
Kavan Palangappa2024-06-14T06:11:35+00:00Our head of SEND Services and Chief Toxicologist at PointCross Life Sciences collaborated on a whitepaper on how to assess your SEND readiness. To access the full document, please click here. We have also summarized the document below. When we check nonclinical studies in SEND format with our SEND-ASSURE service, we find that there are significant inconsistencies...
Benchmark Your SEND Readiness Whitepapers
Kavan Palangappa2024-06-14T06:11:35+00:00Benchmark Your SEND Readiness
Standards and Ontology Driven Workflow Automation of Clinical Studies
Kavan Palangappa2024-06-14T06:11:36+00:00Standards and Ontology Driven Workflow Automation of Clinical Studies - PointCross Life Sciences
Synthetic Dataset
Kavan Palangappa2024-06-14T06:11:37+00:00Synthetic Dataset for Public Use (PC201708)
Integrating Clinical, Biomarker & Disparate Data
Kavan Palangappa2024-06-14T06:11:37+00:00Title: How to Integrate Clinical, Biomarker, and Other Disparate Data Sources May 16, 2017
PointCross Inks two deals for its Xbiom™ Insights – Clinical Biomarker Platform for Precision Medicine Development
Kavan Palangappa2024-06-14T06:11:38+00:00FOSTER CITY, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) — PointCross Life Sciences came out of stealth mode with its Xbiom™ Insights solution for Clinical Biomarker research. With two clients deployed, PointCross is now acquiring new pharma and biotechnology companies who are pursuing precisely targeted therapies in oncology, central nervous system, and cardiovascular. Having proven...